YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Murfreesboro Medical Clinic’s newest ENT physician, Hunter Arnaud, M.D., has recently completed the first Inspire procedure ...

US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending ...

Sleep apnea typically cannot be cured, but the condition is treatable and manageable. Treatment might include lifestyle changes, oral appliances, positive airway pressure, adaptive ventilation devices ...

Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...

I’ve told her how hurtful this feels to me and, potentially, my kids, now that they’re on social media. She assures me she ...

Dear Annie: I just read your column about the woman whose sister-in-law has become exceedingly short-tempered and abusive, ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season continues, other pipeline and regulatory ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

During those vacations and other fun times, when we take group photos together, Adrienne only posts pictures of herself and ...